News | September 02, 2023
USFDA delegation visits Amneal Pharmaceutical facility in Matoda
Amneal’s site in Matoda is one of the company’s 12 pharmaceutical manufacturing facilities
Amneal’s site in Matoda is one of the company’s 12 pharmaceutical manufacturing facilities
The audit was commenced for newly renovated manufacturing Block 1, Block 2, and Block 3
The Tc 99m Mertiatide Injection is used in the diagnosis of congenital and acquired renal abnormalities
The estimated national burden of asthma in India is at 17.23 million with an overall prevalence of 2.05% and out of this, approximately 30 lakh patients can be classified under “inadequately controlled”
A well researched and affordable fixed dose combination, which will significantly improve the glycemic control in adult patients suffering from uncontrolled Type 2 diabetes, especially the ones with comorbidities
The ground floor of the formulation development laboratory is focused on solid orals, the first floor on injections, and the second floor houses the analytical lab
The innovative Fixed-Dose Combination will help improving the glycemic control among adult patients with insulin resistance, those whose diabetes is uncontrolled by metformin; and also those who require addition of Teneliglitptin and Pioglitazone as separate drugs.
The company also reported the issuance of an additional U.S. patent covering the drug, and the filing of a continuation patent application intended to expand patent coverage to other facets of the drug
Acute therapies continue to report strong growth compared to chronic ones.
It is the first company to launch Remogliflozin, Vildagliptin and Metformin combination
Subscribe To Our Newsletter & Stay Updated
